Clinical trial
Phase I/II dose-escalation study of oral administration of the Pan-Histone Deacetylase (HDAC) Inhibitor S 78454 in Hodgkin�s Disease, non-Hodgkin Lymphoma and Chronic Lymphocytic Leukaemia
Phase I part:�
- To assess the MTD and the dose-limiting toxicities (DLTs).�
Phase II part:
- To assess the objective response rate at the recommended dose defined in the phase I part.�
- To assess the safety and tolerability.
Category | Value |
---|---|
Study start date | 2009-10-19 |